Hoya, Eclipse in aesthetic laser pact:
This article was originally published in Clinica
Dental and aesthetic medical laser specialist Hoya ConBio has signed an exclusive three-year distribution agreement with Eclipse Medical for its MedLite C series and RevLite lasers. Eclipse will distribute the lasers in Texas, Louisiana, Arkansas and Oklahoma. Hoya (Freemont, California) claims that the MedLite C series and RevLite lasers, which use Q-switched Nd:YAG laser engineering, represent the next generation of laser engineering. This is because they treat patients via the delivery of energy with a "PhotoAcoustic" effect, as opposed to photothermal energy, which other devices use. These lasers are already used widely for tattoo removal, but also have potential uses for wrinkle reduction, acne scars, vascular and pigmented lesions and hair removal.
You may also be interested in...
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.
A flurry of US biosimilar launches over the past few months has opened several molecules to true, multi-source competition, with a range of pricing strategies seen from competitors. However, some brands that already face biosimilar competition elsewhere in the world are still poised to enjoy a significant period of exclusivity in the US, such as AbbVie’s Humira.
It is the question that continues to exercise the minds of management boards in the medtech industry even as digital health care tools become increasingly ingrained in commercial R&D and operations – and in patient treatment pathways.